Election Roundup: How a Trump Administration Could Shape the Oil and Gas Landscape
Election Roundup: How a Harris Administration Could Shape the Oil and Gas Landscape
No Password Required: MITRE Engage Lead, Innovator in Cyber Deception, and Dance Community Builder
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 196: Regulation Trends in Healthcare and Certificate of Need with Rebecca Thornhill of Maynard Nexsen
Clocking in with PilieroMazza: Second Chance Initiatives: Hiring Workers with Criminal Histories
State AG Pulse | Changing of the Guard in the PNW
Compliance Unveiled: 10 Must-Know Tips for the Pregnant Workers Fairness Act & Independent Contractor Rules
State AG Pulse | Never Say Never to Federal Privacy Legislation
La Reforma Pensional en Colombia
State AG Pulse | Everybody Comes From Somewhere
AI Law in the Commonwealth of Virginia - Recent Developments
The CFPB's Final Credit Card Late Fee Rule: Implications and Industry Response — The Consumer Finance Podcast and Payments Pros: The Payments Law Podcast
Leading With Purpose: Oregon AG Ellen Rosenblum Discusses Her Role at NAAG — Regulatory Oversight Podcast
State AG Pulse | The Election of the Double Haters
Exámenes de constitucionalidad a la reforma tributaria ¿en qué vamos?
Employment Law Now VIII-140 - 7th Anniversary Episode: The Current State of Politics for Employers
Excitement, Turbulence & Confusion: The Top 10 Employment Law Issues That Affected Federal Contractors in 2023
AI in 2024: What Comes Next?
La reforma del sistema de salud
AD Nauseam: Looking in the Crystal Ball: AD Nauseum Predictions and Resolutions for 2024
Most years are eventful for businesses regulated by the US Food and Drug Administration (“FDA”), and 2023 was no exception. 2024 promises more of the same – it being a Presidential election year, some FDA decisions (increased...more
The highly anticipated rule, which would make explicit that LDTs are medical devices subject to FDA oversight, proposes to end the agency's general enforcement discretion approach to such devices....more
The U.S. Food and Drug Administration (FDA) issued a long-awaited revised draft guidance on October 23, 2023, which focuses on communications to healthcare providers (HCPs) regarding scientific information on unapproved uses...more
On June 23, 2023, FDA issued a first-of-its-kind draft guidance for sponsors of studies of psychedelic drugs. The guidance arrived just as the Psychedelic Science 2023 conference in Denver was wrapping up. Touted as the...more
Wednesday, FDA released a letter stating how the agency intends to implement the scope of orphan drug exclusivity awarded to Eagle Pharmaceuticals’ Bendeka (bendamustine HCl) by the D.C. Circuit Court in Eagle...more